Fibromyalgia is a chronic, widespread pain disorder characterised by amplified pain processing in the central nervous system — a phenomenon termed central sensitisation. It is one of the most common causes of chronic musculoskeletal pain, affecting approximately 2–3% of the global population, with a marked female predominance. In South Africa's medical aid system, fibromyalgia is frequently misunderstood by both patients and scheme administrators. It is not a CDL condition, it has no PMB minimum treatment benefit, and management is almost entirely funded from the patient's day-to-day benefits and medical savings account.
What Is Fibromyalgia?
Fibromyalgia is characterised by: - Widespread musculoskeletal pain affecting multiple body regions simultaneously - Fatigue — often severe; disproportionate to physical activity - Sleep disturbances — non-restorative sleep; waking unrefreshed despite adequate duration - Cognitive difficulties ("fibro fog") — impaired concentration, memory, and word retrieval - Heightened sensitivity — to touch (allodynia), light, noise, temperature, and smell
Common co-existing conditions: irritable bowel syndrome (IBS), irritable bladder, anxiety, depression, tension headache, and temporomandibular joint (TMJ) dysfunction. The co-morbidity burden significantly affects the overall cost profile and the benefit limits most likely to be exhausted.
Diagnosis is clinical — based on the 2016 American College of Rheumatology (ACR) diagnostic criteria (widespread pain index and symptom severity scale). There is no blood test or imaging that confirms fibromyalgia; investigations are used to exclude other conditions.
No CDL, No PMB: What This Means for Cover
Fibromyalgia is not listed on the CDL and has no standalone PMB benefit. This has two practical implications: 1. Medications are not funded from a dedicated chronic benefit. They are funded from the medical savings account (MSA) or the above-threshold benefit (ATB) on plans that have one. 2. Benefit limits for allied health professionals (psychologists, physiotherapists) are shared across all conditions — and fibromyalgia management often depletes them faster than the standard plan design anticipated.
Treatment Pathway
Fibromyalgia responds best to a multimodal approach combining pharmacological therapy, structured exercise, psychological therapy, and patient education. No single treatment is curative — the goal is symptom reduction and functional improvement.
Exercise — first-line non-pharmacological: Aerobic exercise and strength training are the best-evidenced interventions in fibromyalgia. Even modest exercise programmes (walking 20–30 minutes/day, three times per week) reduce pain severity over time. Most plans do not directly fund an exercise programme — it is a self-managed therapy. Physiotherapy benefit can be used for supervised initial programme design.
Cognitive Behavioural Therapy (CBT): CBT delivered by a clinical psychologist is the best-evidenced psychological treatment for fibromyalgia. It addresses pain catastrophising, activity avoidance, sleep hygiene, and coping strategies. Most plans provide 10–20 psychology sessions per year under the mental health outpatient benefit. This is typically the first benefit to be exhausted for fibromyalgia patients engaging in genuine therapeutic CBT.
Medications — evidence and cost:
Amitriptyline (10–75mg nocte): A tricyclic antidepressant used at sub-antidepressant doses for pain modulation and sleep. Inexpensive (~R120/month). Evidence-based; guideline-endorsed. Available on all formularies.
Duloxetine (Cymbalta, 60–120mg daily): An SNRI with both pain-modulating and antidepressant/anxiolytic effects. Monthly cost: approximately R650–R800. Good evidence for fibromyalgia. Non-formulary on some plans.
Pregabalin (Lyrica, 150–450mg daily): A calcium channel alpha-2-delta ligand; reduces central sensitisation and pain transmission. Monthly cost: approximately R700–R900. Schedule 5 in SA (requires specialist prescription). Good evidence for fibromyalgia-related pain and sleep.
Tramadol (short-term only): A weak opioid with serotonin-noradrenaline reuptake inhibition. Useful for acute pain episodes. Dependence risk with long-term use; not recommended as maintenance therapy. Monitor carefully.
Cyclobenzaprine: Muscle relaxant with modest evidence for improving sleep in fibromyalgia. Inexpensive.
Important: Standard NSAIDs and opioids (other than tramadol) are not effective for fibromyalgia pain and are not recommended as treatment.
Physiotherapy: Supervised aerobic conditioning, hydrotherapy, and graded activity programmes. Most useful in the early active management phase. Most plans limit physiotherapy to 10–20 sessions/year — insufficient for long-term fibromyalgia management. Rehabilitation should focus on building an independent home exercise programme.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Mild fibromyalgia — amitriptyline + GP review only | R5,000 – R12,000 |
| Moderate — amitriptyline + duloxetine/pregabalin + rheumatologist + psychologist | R20,000 – R40,000 |
| Complex — multiple specialists + CBT programme + full allied health utilisation | R35,000 – R70,000 |
Gap Cover Relevance: Low
Fibromyalgia rarely results in hospitalisation. The primary financial exposure is depletion of day-to-day and allied health benefits (psychology, physiotherapy) — not specialist surgical shortfalls. Gap cover is not a primary recommendation for fibromyalgia as the main condition.
Plan Selection: What Matters Most
The most important plan selection factor for fibromyalgia is not the medication benefit — it is the allied health benefit structure:
- Psychology/CBT sessions: How many sessions per year? Is there a separate mental health outpatient benefit? Is CBT covered?
- Physiotherapy limit: 10 sessions is inadequate for an exercise-focused management approach. Plans with more generous physio limits or no annual limit per chronic motivation are preferable.
- Rheumatologist and pain specialist coverage: Ongoing specialist review and pain clinic access.
- Above-threshold benefit (ATB): Once MSA is depleted, the ATB catches day-to-day costs that exceed the MSA on comprehensive plans. This is particularly relevant for fibromyalgia given the ongoing medication and allied health costs.
Talk to Eldon
See which plans pay for fibromyalgia →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).